Zentalis Pharmaceuticals (ZNTL) Income towards Parent Company (2019 - 2026)

Zentalis Pharmaceuticals' Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$35.4 million for Q1 2026.

• In Q1 2026, Income towards Parent Company rose 26.78% year-over-year to -$35.4 million; the TTM figure through Mar 2026 stood at -$124.1 million (up 43.82% YoY), while the FY2025 annual figure was -$137.1 million, up 17.37% from the prior year.
• Income towards Parent Company was -$35.4 million for Q1 2026 at Zentalis Pharmaceuticals, roughly flat from -$35.2 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $10.0 million in Q1 2024 to a low of -$99.0 million in Q2 2023.
• Historically, Income towards Parent Company has averaged -$49.2 million across 5 years, with a median of -$48.4 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Income towards Parent Company soared 116.42% in 2024, then tumbled 580.87% in 2025.
• A 5-year view of Income towards Parent Company shows it stood at -$48.4 million in 2022, then fell by 26.17% to -$61.0 million in 2023, then gained by 22.24% to -$47.5 million in 2024, then rose by 25.82% to -$35.2 million in 2025, then declined by 0.39% to -$35.4 million in 2026.
• The last three Income towards Parent Company figures came in at -$35.4 million (Q1 2026), -$35.2 million (Q4 2025), and -$26.7 million (Q3 2025), per Business Quant data.